FDA Reorganization Will Not Include John Taylor As Top Aide To Commissioner
This article was originally published in The Gray Sheet
John Taylor’s exit from the agency comes as FDA Commissioner Margaret Hamburg awaits recommendations from a panel of senior agency officials on how to ensure the centers support Office of Regulatory Affairs’ activities without duplication.
You may also be interested in...
FDA Chief Scientist Jesse Goodman leaves agency. New FDA deputy commissioner for global regulatory operations and policy appointed. Boston Scientific names new chief medical officer. More people briefs.
The mandates in the FDA Safety and Innovation Act and Drug Quality and Security Act show a lot of congressional confidence in the agency, but FDA commissioner says that members also must provide resources to go with it.
While Mylan wants Autor to help push quality improvement efforts around the world, her departure from FDA may affect implementation of similar plans at the agency.